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Background: Mesenteric stenting has not been widely adopted for the treatment of chronic mesenteric ischemia (CMI).
The recent availability of embolic protection and low-profile devices with the theoretical ability to decrease perioperative
bowel necrosis, led us to begin using mesenteric stenting for patients with CMI. We review our initial experience to
examine short-term outcomes.
Methods: We performed a retrospective analysis of all patients who were treated by vascular surgeons with mesenteric
stenting for CMI. Patients with acute mesenteric ischemia were excluded. We evaluated perioperative morbidity and
mortality, restenosis, recurrent symptoms, and reintervention. Kaplan-Meier methods were used to assess events during
follow-up. We also compared these outcomes with a historical control group of patients treated with open surgical
revascularization.
Results: Fourteen patients underwent mesenteric stenting over the past 3 years. Mean age was 73, and 64% were women.
There was no perioperative or 30-day mortality or major morbidity. Early restenosis and recurrent symptoms occurred
in 10% and 9% of patients at 6 months. At a mean follow-up of 13 months, 53% of patients underwent reintervention.
However, 93% were symptom-free at their last follow-up. Compared with open surgery, stent patients had lower
perioperative major morbidity (30% vs 0%, P < .01) and shorter hospital and intensive care unit length of stay (median
10 days vs 2 days, and 3 days vs 0 days, respectively, P< .01 for both). However, stent patients were seven times as likely
to develop restenosis (P< .01), four times more likely to develop recurrent symptoms (P< .01), and 15 times more likely
to undergo reintervention (P < .01). There was one death 13 months after stenting due to mesenteric infarction in a
patient lost to follow-up. One patient was successfully converted to open surgery after a second restenosis. He had
regained 20 pounds and was determined to be a better operative candidate than at his initial presentation. There was no
perioperative or 30-day mortality or major morbidity with reintervention after mesenteric stenting.
Conclusion: Mesenteric stenting for CMI can be performed with low perioperative risk. However, stenting is associated
with early restenosis and recurrent symptoms requiring secondary procedures. Patients with severe nutritional depletion
or high surgical risk may benefit from mesenteric stenting for CMI, but close follow-up is required. Later open surgery
can be performed for restenosis if nutritional status and surgical risk are improved, or repeat angioplasty and stenting can
be effectively performed if operative risk remains high. (J Vasc Surg 2005;42:268-74.)Percutaneous angioplasty and stenting has become
widely accepted for iliac and renal atherosclerotic occlusive
disease and has replaced open bypass or endarterectomy for
most patients. This approach results in lower morbidity and
mortality and shorter hospital length of stay. Angioplasty
and stenting are beginning to replace bypass or endarterec-
tomy in some patients with infrainguinal and carotid occlu-
sive disease as well. However, the role of stenting in the
management of chronic mesenteric ischemia (CMI) re-
mains less defined.
CMI remains a morbid disease affecting an increasing
number of individuals, possibly the result of an aging
population. Optimal management of CMI involves early
diagnosis and revascularization when possible to prevent
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268disease progression, ameliorate pain, and prevent possible
death from development of acute mesenteric ischemia.
Patients with CMI usually have many comorbidities and
significant perioperative risk1-4 Perioperative mortality for
open revascularization is typically 5% to 15%, with up to
30% of patients experiencing major perioperative morbid-
ity, including myocardial infarction, acute renal failure,
respiratory failure, mesenteric infarction, or multiorgan
dysfunction.5-7
Approximately half of patients with CMI have signifi-
cant coronary artery disease and peripheral vascular dis-
ease.1 Weight loss occurs in 84% to 100% of CMI patients,
often resulting in significant malnutrition that has been
demonstrated to increase major morbidity and mortality
twofold to tenfold in patients undergoing major intra-
abdominal surgery.5,6,8,9
Open surgery remains the mainstay of treatment for
CMI, but some have reported successful mesenteric stent-
ing for CMI.7,10-13 Early reports demonstrated technical
success rates from 92% to 100% in stent procedures for
CMI. These series had perioperativemortality rates of 0% to
10% and perioperative morbidity from 0% to 17%. Periop-
erative bowel infarction has been reported in these series.
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necrosis in one report, this is typically noted immediately at
the time of stenting.14 In other series, bowel necrosis has
been reported without mention of specific cause.7,13
We hypothesized that embolizationmay be the cause in
some of these cases. With the recent availability of embolic
protection devices and low-profile (0.014 and 0.018 inch)
stent systems, we began treating CMI patients with mesen-
teric stenting, because we believed that these systemsmight
reduce complications. The purpose of this study was to
review the early results of our initial series of CMI patients
treated with stents. We also compared these outcomes with
those of a historical control group of patients undergoing
open surgery for CMI.
METHODS
The clinical records of all patients undergoing mesen-
teric stenting for CMI by vascular surgeons at Dartmouth-
Hitchcock Medical Center from 2000 to 2004 were retro-
spectively reviewed. The diagnosis of CMI was entertained
according to clinical symptoms, including postprandial ab-
dominal pain, food fear, and weight loss. The diagnosis was
confirmed initially with duplex ultrasonography or com-
puted tomography angiography, and eventually with arte-
riography at the time of treatment. Duplex criteria for
significant stenosis (50%) of the celiac artery was defined
as peak systolic velocity (PSV) 200 cm/s and end-
diastolic velocity (EDV) 55 cm/s. Significant stenosis
(50%) of the superior mesenteric artery (SMA) was de-
fined as PSV  300 cm/s and EDV  45 cm/s.15 Patients
presenting with acute mesenteric ischemia were excluded.
Technical success for stenting was defined as postintervention
residual stenosis 30% by arteriography and 10 mm Hg
pressure gradient.
Demographic information, co-morbid medical condi-
tions, diagnostic test findings, operative reports, postoper-
ative hospital courses, and mortality were obtained from
the medical record and the Social Security Death Index.
Major morbidity was defined as a combined endpoint of
myocardial infarction, acute renal failure, respiratory fail-
ure, bowel infarction, or multiorgan dysfunction syn-
drome. Follow-up included assessment of the patients’
symptoms and follow-up duplex scan evaluation of the
treated arteries. Recurrent symptoms were defined as ab-
dominal pain, nausea, or diarrhea. Follow-up duplex sur-
veillance studies were obtained at 1, 3, and 6 months
initially and every 6 months thereafter. Restenosis was de-
fined using the duplex criteria defined for 50% stenosis.
Comparison was made with a historical control group
of patients undergoing open surgical revascularization dur-
ing 1990 to 2004. The clinical records of all patients
undergoing open surgical revascularization during this pe-
riod were similarly reviewed retrospectively for periopera-
tive outcomes, recurrent symptoms, restenosis, reinterven-
tion, and survival as described.
Mesenteric stenting was typically performed via a left
brachial artery approach, through which a 6F angled guid-
ing catheter or sheath was placed at the level of the mesen-teric vessels. Anteroposterior aortography demonstrated
the mesenteric arcade before instrumentation of the mes-
enteric vessels. Lateral aortography demonstrated the loca-
tion of the orifices of themesenteric vessels andwas used for
stent placement.
Lesions were crossed with a 0.014-in or occasionally a
0.018-in wire, and a 4F glide catheter was advanced across
the lesion. The 0.014-in Medtronic GuardWire embolic
protection device (Minneapolis, Minn) was then inserted
through the catheter and inflated at a distance that would
allow adequate room for stent delivery (typically proximal
to the first branch vessel). Alternatively, the FilterWire EX
(Boston Scientific, Natick, Mass) was advanced and the
filter deployed distal to the lesion. Balloon-expandable
0.014-in stents (Herculink, Guidant, Indianapolis, Ind)
were deployed across the lesion and positioned to extend 1
to 2 mm into the aortic lumen. Stents were dilated to the
diameter of the normal arterial lumen.
If the GuardWire was used, the column of blood was
then aspirated and the Guardwire balloon was deflated.
Contrast arteriography was repeated and pressure gradients
were checked. Further dilation was performed as needed to
obtain a gradient10 mmHg and30% residual stenosis.
If the FilterWire was used, contrast injection and pressure
measurements were made after stent placement and before
recapture and removal of the filter. Anteroposterior aortog-
raphy was then repeated to observe any changes in filling of
the mesenteric arcade.
After stenting, patients were treated with aspirin (325
mg) and clopidogrel (75 mg/day) for 30 days, after which
aspirin was continued indefinitely.
For statistical analysis, categoric variables were com-
pared with 2 or Fisher’s exact test, and continuous vari-
ables were compared with a two-sample t test or Wilcoxon
rank sum test, as appropriate. Kaplan-Meier life table anal-
ysis was used to estimate survival, restenosis, recurrent
symptoms, and reintervention. Comparisons were made
with the log rank test. P  .05 was considered significant.
RESULTS
Fourteen patients underwent mesenteric stenting from
2001 to 2004. The mean age was 73, and 64% were
women. All had stenosis or occlusion of both the SMA and
celiac artery. All had post-prandial pain. Weight loss was
seen in 71% (mean weight loss, 11 kg), and food fear was
elicited in 57%.
Eighteen arteries were stented in the 14 patients (Table I).
Eight patients underwent SMA stenting alone, 4 had SMA
and celiac stents, and 2 had celiac stenting alone. Stent
diameters ranged from 5 to 7 mm. All celiac stenoses were
treated with a single stent, and a mean of 1.5 stents were
used in SMA lesions. Embolic protection was used in 13 of
14 patients (17 of 18 arteries). The GuardWire was used in
12 patients and the FilterWire was used in one. The single
case in which no protection was used was a celiac lesion
with retrograde flow in the hepatic artery. Technical success
was achieved in 93% of patients. One patient had a postpro-
cedure residual gradient across an SMA stent of 40mmHg.
JOURNAL OF VASCULAR SURGERY
August 2005270 Brown et alThe celiac artery could not be crossed at that time. This
patient later underwent restenting of the SMA and success-
ful celiac stenting after recurrent symptoms developed.
Immediate outcome. There was no perioperative or
30-day mortality or major morbidity. Median hospital
length of stay was 2 days. All patients had initial symptom
relief after mesenteric stenting.
Recurrence. Mean length of follow-up was 13 months.
Restenosis developed in eight patients (57%)during follow-up
and all underwent reintervention. Restenosis detected by
duplex scanning was confirmed with arteriography in all
eight patients. Seven had recurrent symptoms. One patient
was asymptomatic with a progressive restenosis of the SMA
and had a prior celiac occlusion.
The mean time to reintervention was 9 months (range,
2 to 22 months). Reintervention included angioplasty of
in-stent restenosis in two patients, restenting of lesions at
the edge of or beyond the initial stent in five patients, and
aorta to SMA bypass in one patient. There was no mortality
or major morbidity with reintervention.
The patient who underwent a bypass had an initial
recurrence at 2 months that was treated with angioplasty of
the in-stent restenosis and stenting of the restenosis at the
edge of the initial stent. He was symptom free at this time
but was treated because of the rapid recurrence combined
with a prior celiac occlusion. He had no residual gradient or
angiographic stenosis at completion of both procedures.
He once again developed restenosis at 8 months. At this
time he had regained 20 pounds and was judged to be a
better candidate for open revascularization than at his
initial presentation. He underwent open bypass grafting,
had an uncomplicated postoperative course, and was doing
well at 10 months postoperative. The bypass procedure was
not complicated by the presence of the stents.
One patient with restenosis had repeat angioplasty at 7
months. She later failed to attend follow-up, acute intesti-
nal ischemia developed, and she died 13 months after the
initial procedure. One patient died of other causes at 14
months. At a mean follow-up of 13 months after stenting,
Table I. Stent procedures performed in 14 patients with
chronic mesenteric ischemia
Arteries stented
SMA and celiac 4
SMA alone 8
Celiac alone 2
Stent diameter
5 mm 5
6 mm 12
7 mm 1
Sents per vessel
Celiac 1
SMA 1.5
Embolic Protection (patients)
GuardWire 12
FilterWire EX 1
SMA, Superior mesenteric artery.53% underwent repeat angioplasty, or stenting or both;27% were alive with primary patency, one underwent con-
version to surgery, and two died (Fig 1).
Outcome comparison with a historical control group
Between 1990 and 2004, 33 patients underwent open
revascularization, 28 underwent bypass grafting, and 6
underwent endarterectomy/thrombectomy (one patient
had both endarterectomy and bypass) (Table II). Com-
pared with open surgery patients, stent patients tended to
be older and were somewhat more likely to have coronary
artery disease, prior myocardial infarction, chronic renal
insufficiency, hypertension, chronic obstructive pulmonary
disease, hyperlipidemia, and cerebrovascular accident (Ta-
ble III). Most patients in both groups were women. Pre-
sentation was similar in both groups (Table IV). Postpran-
dial abdominal pain, weight loss, and food fear were the
most common presenting signs and symptoms.
Morbidity and mortality. The perioperative mortal-
Fig 1. Outcomes in patients undergoing stenting for chronic
mesenteric ischemia at a mean follow-up of 13 months.
Table II. Open procedures performed in patients with
chronic mesenteric ischemia
Procedure No of patients
Total 33
Bypass Only 27
Prosthetic
SMA 6
Celiac  SMA 15
Celiac  SMA  IMA 2
Celiac  IMA 2
Vein
SMA  IMA 2
Combination/Other Procedures 6
Aorto-SMA bypass  celiac endarterectomy 1
Transaortic celiac  SMA endarterectomy 1
Transaortic SMA endarterectomy 2
SMA thrombectomy  vein patch angioplasty 2
SMA, Superior mesenteric artery; IMA, inferior mesenteric artery.ity rate was 9% in the open surgery group and 0% in stent
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occurred after 36 and 100 days from respiratory and renal
failure, and one after 1 week from respiratory failure.
Eleven patients (30%) in the open surgery group had
major perioperative morbidity consisting of respiratory fail-
ure (n  8), myocardial infarction (n  2), renal failure (n
Table III. Demographic data and comorbidities in
patients with chronic mesenteric ischemia undergoing
mesenteric stenting or open revascularization
Stent Open P
N 14 33
Age (mean) 73 65 .08
Gender (% female) 64% 82% .19
CRI 29% 9% .17
History of MI 36% 15% .12
COPD 36% 15% .12
Hypertension 93% 67% .08
CAD 57% 42% .37
DM 21% 18% 1.0
Current smoker 64% 67% .63
CRI,Chronic renal insufficiency;MI,myocardial infarction;COPD, chronic
obstructive pulmonary disease; CAD, coronary artery disease; DM, diabetes
mellitus.
Table IV. Presentation of patients with chronic
mesenteric ischemia who underwent mesenteric stenting
or open revascularization
Stent Open P
Abdominal pain 100% 88% .18
Weight loss 71% 76% .93
Mean weight loss (kg) 11.1 9.4 .67
Food fear 57% 58% .87
Mean time to diagnosis (months) 10 11 .79
Mean pre-op WBC (cells  103/L) 7.8 9.6 .01
Mean pre-op creatinine (mg/dL) 1.0 0.9 .45
Diseased vessels
Celiac axis 100% 94% .36
Superior mesenteric artery 100% 94% .36
Inferior mesenteric artery 36% 64% .09
WBC, White blood cells.
Table V. Perioperative outcomes in patients with
chronic mesenteric ischemia undergoing mesenteric
stenting or open revascularization
Stent Open P
Perioperative death 0% 9% .25
Major perioperative morbidity 0% 30% .01
Median ICU LOS (days) 0 3 .01
Median intubation time (days) 0 2 .01
Median hospital LOS (days) 2 10 .01
Discharged home 100% 75% .06
Discharged to facility 0% 15% .06
ICU, Intensive care unit; LOS, length of stay. 5), and multiorgan dysfunction syndrome (n  2).Major perioperativemorbidity was significantly lower in the
stent group (0%, P  .01).
Intensive care unit length of stay (LOS) was longer in
the open surgery group (median, 2 days) compared with
the stent group (median, 0 days, P  .01). Hospital LOS
was significantly longer in the open surgery group (median,
10 days) compared with the stent group (median, 2 days,
P  .01).
Fifteen percent of open surgery patients were dis-
charged to a rehabilitation facility or nursing home. All
stent patients were discharged home. Survival at 1, 5, and
10 years was 85%, 68%, and 38% in the open surgery group,
whereas 1-year survival in stent patients was 89% (Kaplan-
Meier estimates, with standard error 10% for all time
points).
Recurrence. Length of follow-up was substantially
longer for open surgery patients (mean, 34 months) com-
pared with stent patients (mean, 13 months). A postoper-
ative duplex examination was performed in 94% of open
surgery patients and 100% of stent patients. Because of the
small number and short follow-up in the stent patients,
Kaplan-Meier estimates of restenosis, recurrent symptoms,
and reintervention are valid only to 6 months in this group.
Restenosis at 6 months was 9% in stent patients and 0%
for open surgery patients. Over time, stent patients were
seven times more likely to develop restenosis than open
surgery patients (P  .05) (Table VI). No difference was
seen in the rate of restenosis between patients undergoing
single versus two-vessel stenting. Half of the patients with
two-vessel stents (2 of 4) and 60% (6 of 10) patients with
single-vessel stents eventually underwent reintervention.
Recurrent symptoms were seen in 9% of both stenting and
open surgery groups at 6 months, but over time, stent
patients were four times as likely to develop recurrent
symptoms (P  .01) (Table VI).
Reintervention was performed in 8% of stent patients at
6 months versus 7% for open surgery patients. However,
over time, stent patients were 15 times as likely to undergo
revision as open surgery patients (P  .01) (Table VI). At
the last follow-up, eight stent patients (57%) underwent
repeat procedures for recurrent symptoms, restenosis, or
both.
Although many stent patients required one or more
reinterventions for restenosis and recurrent symptoms, 93%
were symptom-free at their last follow-up. There was no
Table VI. Outcomes during follow-up in patients with
chronic mesenteric ischemia undergoing mesenteric
stenting or open revascularization
Variable HR 95% CI P
Restenosis 7.3 2.2-24.5 0.01
Recurrent symptoms 3.7 1.03-13.3 .05
Reintervention 14.7 3.0-70.9 .01
Freedom from symptoms 0.43 0.05-3.6 .42
HR, Hazard ratio; CI, confidence interval.difference in overall freedom from symptoms (after reinter-
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tients (P  NS) (Table VI).
DISCUSSION
This series reflects an evolution in our management of
patients with CMI. We obtained access to embolic protec-
tion devices in 2001. Since then, because of the high
morbidity and mortality associated with open surgery, we
have attempted stenting in nearly all patients, which we hy-
pothesized would reduce the risk of potentially catastrophic
embolization. Thus, since 2001, 14 of 16 patients have un-
dergone primary stenting, whereas only two have undergone
primary open surgery for the initial treatment of CMI.
Our early results suggest that stenting of mesenteric
arteries using embolic protection can be performed with a
high rate of success and low rates of perioperative organ
failure, myocardial infarction, bowel infarction, and death.
Stent patients spend fewer days in the hospital and return to
normal activity relatively quickly. However, our data also
suggest that this approach to this disease results in a higher
restenosis rate and a higher rate of secondary intervention
compared with open surgical revascularization.
Published results for CMI patients treated with angio-
plasty and stenting are difficult to interpret because of
continuous changes in technique and the limited numbers
of patients in reported series. Because CMI is a relatively
rare disease, many years are required at most institutions to
accumulate enough patients to draw any conclusion about
this approach.
In 1996, Allen et al14 reported their 10-year series of 19
high-risk CMI patients who underwent angioplasty only.
The perioperative mortality rate was 5%. Seventy-nine per-
cent of patients had relief of symptoms, with 20% develop-
ing recurrent symptoms at a mean of 28 months. Two
patients (11%) had repeat angioplasty.
AbuRahma et al16 recently reported their series of 24
patients who underwent stenting for chronic mesenteric
ischemia. Technical success was achieved in 96% of patients.
No perioperative major morbidity or mortality occurred.
Follow-up surveillance was performed using duplex ultra-
sonography scanning over a mean follow-up period of 26
months. Recurrent symptoms were noted in 21% at 6
months. Restenosis was seen in 35% at 1 year. Two-year
survival was 93, and no deaths occurred as a result of
mesenteric ischemia.
In 2002, Matsumoto et al10 reported their 15-year
series of 33 patients, 21 of whom underwent angioplasty
alone and 12 of whom had stenting. Technical success,
defined as postprocedure stenosis of30% was achieved in
81% of angioplasty-only patients and in 100% of stent
patients. No perioperative deaths occurred, but major com-
plications were seen in 13%. Four (12%) patients had per-
sistent symptoms. Mean follow-up was 38 months. Clinical
success, defined as relief of symptoms, was achieved in 82%
of patients. Workup for restenosis was done only in patients
with recurrent symptoms. Six (18%) of the 33 patients
underwent repeat procedures for restenosis.Kasirajan et al,7 in 2001, reported their 3.5-year expe-
rience with 28 patients who underwent mesenteric stenting
and compared the outcomes with 85 of their open surgery
patients. Mean follow-up was 2 years in stent patients. They
found no difference in the incidence of postoperative com-
plications between the two groups. Perioperative mortality
was 8.2% in the open surgery group and 10.7% in the stent
group. Bowel necrosis occurred in two of 28 stent patients.
The stent group had a shorter hospital LOS and a higher
incidence of recurrent symptoms compared with the open
surgery group.
The lower perioperative morbidity and mortality rates
reported in our series may be associated with the use of a
low-profile (0.014-in) system and embolic protection de-
vices. We believe these measures minimize the risk of
embolization with subsequent intestinal infarction, but this
cannot be proven from the small number of patients in this
series. Although we did not perform routine analysis of the
aspirate because we lacked a filtering device for the Guard-
Wire system, macroscopic debris was noted on several
occasions. To our knowledge, this is the first report to
demonstrate the feasibility of embolic protection with mes-
enteric stenting.
The rate of restenosis in this series is higher than that
reported by others.10,11,13 This may be because our reste-
nosis rate was higher or because we detected stenosis more
accurately with frequent duplex scanning. AbuRahma
et al16 also noted high recurrence rates and also performed
routine duplex surveillance. Our practice was to dilate
arteries being stented to a diameter equal to that of the
native vessel. It is possible that a more aggressive dilation
would have resulted in fewer restenoses. The timing of
follow-up surveillance is not outlined in most reports.
Aggressive routine duplex examination and office visits in
our follow-up period may have resulted in more frequent
detection of restenosis, both in those who were symptom-
atic and those who were asymptomatic, including those
who would be considered asymptomatic because they did
not seek medical attention. (Table VI and Fig 2).
The high rate of recurrent symptoms could be due to
the low proportion of patients (4 of 14) in whom both the
celiac and SMA were treated. We initially chose to treat
patients with a single vessel revascularization, preferably the
SMA, to decrease the risk of catastrophic complications if
both the celiac and SMA were treated and occluded. As we
gained experience and as we noted the frequency of early
recurrences, we began to treat both the celiac and SMA
unless one of these vessels was occluded. We typically avoid
crossing occlusions because of the potential for emboliza-
tion as well as an expectation of lower patency. Only one
chronic total occlusion was treated in our series. This
patient had gained 25 pounds and was asymptomatic with-
out restenosis at 10 months after stenting.
Our series also suggests a possible role for mesenteric
stenting as a temporizing measure in debilitated, malnour-
ished patients. Our patient who underwent initial stenting
and had subsequent weight gain followed by open surgery
demonstrates this potential. The impact of nutritional sta-
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Others have seen that attempts to improve nutrition status
with preoperative total parenteral nutrition have not re-
sulted in improved outcomes in patients undergoing open
mesenteric revascularization.5
We believe stenting has an important role in high-risk
patients who are severely malnourished as a result of mes-
enteric ischemia. Such patients are at increased risk for
postoperative complications,9 and a minimally invasive ap-
proach for initial intervention will potentially minimize this
risk. These patients should be followed closely with routine
duplex examinations for detection of restenosis or the
development of recurrent symptoms. In the event of reste-
nosis, an open surgical revascularization can be performed
early, with the advantage of improved nutritional status and
modification of other risk factors. Alternatively, those who
remain at high risk for open surgery may be managed with
repeat stenting or angioplasty of in-stent restenosis.
This study has several limitations:
● The small number of patients limits the ability to
estimate event rates or evaluate differences between
the stent and open-surgery groups.
● Because of the recent adoption of this technique, the
follow-up period with stent patients is relatively short,
thus limiting the ability to draw conclusions about the
long-term risks and benefits of this treatment.
● Comparisons with patients undergoing open surgery
suffer from the use of a historical control group with
potentially different indications for intervention and
follow-up practices.
● Duplex surveillance was performed regularly in the
stented group but rarely after open repair, so the
recurrence rate may be underestimated in the open-
repair group.
Open surgery remains a valuable treatment method for
CMI, but its reported mortality and morbidity suggest that
it is best applied to lower-risk patients. Stenting is more
applicable to higher-risk patients and those who have be-
Fig 2. Kaplan-Meier estimates of freedom from resteno
stenting or open revascularization (P  .01 log-rank te
Dotted line indicates standard error 10%.come nutritionally depleted, but it has a high recurrencerate. For this reason, careful follow-up with duplex scan-
ning is important.
For some patients, initial stenting may provide good
bridge therapy so that open surgery can later be performed
when nutrition is better and other surgical risks are opti-
mized. For those with ongoing high risk for open surgery,
repeat intervention can safely be performedwith short-term
symptom relief in almost all patients.
Long-term follow-up with larger numbers will be nec-
essary to ultimately determine the appropriate role of mes-
enteric stenting for CMI. Evolving techniques may im-
prove results with stenting and lower recurrence rates. We
believe that embolic protection may have a role in this
treatment. (Fig 2).
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